Helicobacter pylori (H. pylori) causes chronic gastritis. The inducible prostaglandin synthetase cyclooxygenase 2 (COX-2) plays an important role in inflammatory conditions. We hypothesized that H. pylori-associated chronic gastritis would express COX-2 protein. Our aim was to evaluate the effect of eradication of H. pylori infection on COX-2 expression in the antral mucosa of patients before and after antibiotic therapy.
INTRODUCTION
Helicobacter pylori (H. pylori) infection causes a characteristic local inflammatory response in the gastric mucosa, leading to a chronic gastritis. Although the majority of individuals have a clinically silent infection, diverse outcomes of the infection have been identified. These include not only the development of peptic ulcer disease, but also an increased risk of neoplastic transformation in the stomach, including noncardia adenocarcinoma and mucosa-associated lymphoid tissue lymphoma (MALTomas). This organism clearly has had a significant impact on the management of many upper gastrointestinal disorders. The public health debate regarding the role of widespread eradication of H. pylori infection remains ongoing.
Prostaglandins play an important physiological role in the protection of the upper gastrointestinal (GI) tract mucosa against injurious agents. Until recently, prostaglandin production in the gastroduodenal mucosa was thought to be due to a single isoform of cyclooxygenase (1) . Recognition of an inducible isoform, cyclooxygenase-2 (COX-2), which plays a critical role for prostaglandin (PG) synthesis in inflammatory states, raises a question regarding the contribution of the various COX isoforms in mucosal prostaglandin levels. Analogous to the observation that other chronically inflamed tissues express increased amounts of COX-2 protein (2), H. pylori-associated chronic gastritis would be expected to express COX-2 protein, at least in infiltrating inflammatory cells. Although COX-2 is not present at significant levels in normal gastric mucosa (3), a recent report has suggested that COX-2 expression was increased at the edges of experimental gastric ulcers created in laboratory animals, and that COX-2 may be the source of prostaglandins important for ulcer healing (4) . The role of COX-2 in inflamed gastric tissue is uncertain; however, if COX-2 has an essential role in healing, this may have important clinical implications for the potential clinical impact of highly selective COX-2 inhibitors currently in development for the management of arthritis. Although these agents do not appear to induce GI toxicity, their effect on prostaglandins potentially important in ulcer healing may have detrimental actions in patients with established peptic ulcer disease.
The International Agency for Research on Cancer has classified H. pylori as a group I carcinogen, a definite cause of gastric cancer in humans (5) . Although the organism does not invade the gastric epithelium, bacterial factors lead to an intense inflammatory cell infiltrate with associated cytokine production, which perpetuates inflammation. H. pylori also induces inflammatory cells to produce reactive oxygen metabolites, which may damage DNA and promote carcinogenesis. Bacterial products, in combination with cytokines, lead to increases in basal and stimulated gastrin levels. In some patients, H. pylori-induced gastritis extends proximally from the antrum, where it is typically seen, to the body of the stomach. There, inflammation of the glandular stomach leads to chronic atrophic gastritis, low acid production despite hypergastrinemia, and a decreased risk of ulcer disease, but an increased risk for gastric malignancy (both adenocarcinoma and lymphoma). Because the induction of COX-2 expression has been shown to have an important role in the progression of neoplastic transformation in the colon, it may also play a role in the development of H. pylori-associated gastric neoplasia. Indeed, COX-2 expression has been demonstrated in human gastric carcinoma tissue by immunohistochemistry (6) .
Because H. pylori-associated changes in COX-2 expression in the gastric mucosa have implications for both peptic ulcer disease and neoplasia, we sought to evaluate the COX-2 expression in the antral mucosa of patients before and after eradication of H. pylori infection. We also correlated this expression with the histological changes of inflammation.
MATERIALS AND METHODS

Patients
Tissues were obtained from patients with nonulcer dyspepia undergoing H. pylori eradication in a randomized controlled trial (7) . Patients with nonulcer dyspepia (normal endoscopy) received bismuth subsalicylate 524 mg q.i.d. for 4 wk with metronidazole 250 mg q.i.d. for the first 2 wk of therapy (eradication rate ϭ 68%). The success of antibiotic therapy was assessed by histology 4 wk after completion of therapy. Ten patients with nonulcer dyspepsia with proven H. pylori infection and subsequent successful eradication comprised the study group. Three biopsies of antral mucosa were evaluated immunohistochemically for the presence of COX-2 protein expression before and after successful eradication of H. pylori infection.
Immunohistochemistry
Immunohistochemical staining for COX-2 was performed using the Vectastain ABC-AP kit (Vector Laboratories, Burlingame, CA). The sections were deparaffinized, then preincubated with 0.5% bovine serum albumin (BSA) in PBS and diluted normal goat serum (1:66.7) for 20 min. Sections were then incubated with antibody to COX-2 (Cayman Chemical, Ann Arbor, MI) diluted 1:100 in 0.5% BSA in PBS or normal rabbit IgG overnight at 4°C. This rabbit polyclonal IgG antihuman COX-2 antibody has no crossreactivity with sheep seminal vesical COX-1 (data on file, Cayman Chemical). The antibody also demonstrated no crossreactivity with human COX-1 in Western blots in our laboratory (data not shown). Sections were washed three times in PBS, then incubated for 1 h with goat antirabbit IgG at a dilution of 1:1000. Sections were further washed and incubated with an avidin and biotinylated alkaline phosphatase complex for 30 min. Finally, the sections were washed and color was developed by immersion in alkaline phosphatase substrate solution (Vector Laboratories) for 1 h. Sections were rinsed in water and counterstained with hematoxylin. Positive staining was indicated by a red color. Control stains with normal rabbit IgG were uniformly negative.
Histological Scoring
The presence and amount of acute and chronic inflammation were evaluated in 20 hematoxylin-and-eosin-stained formalin-fixed paraffin-embedded gastric biopsies from 10 patients. Chronic inflammation was defined as plasma cells in the lamina propria. The number of plasma cells in the lamina propria was graded semiquantitatively from 1-4, with 1 being a small number of plasma cells and 4 being a marked number. Acute inflammation was defined as neutrophils infiltrating gastric epithelial cells. Acute inflammation was graded semiquantitatively from 1-3. Grade 1 was one focus of activity per biopsy, 2 was 2-3 foci per biopsy, and 3 was Ͼ 3 foci per biopsy, representing intense acute inflammation.
Immunohistochemical staining for COX-2 was assessed by counting the number of positive and negative staining cells on the surface of each biopsy. The pathologist was blinded to the H. pylori status of the patient and, as the slides were not counterstained, the degree of inflammation or presence of bacteria was difficult to discern. Cell counting was performed on the strongest staining region of each biopsy. Cell counts were restricted to the surface epithelium because the vast majority of positively staining cells were 
RESULTS
Specific immunostaining for COX-2 was observed in the antral mucosa of patients infected with H. pylori (Fig. 1) . Patchy cytoplasmic staining was seen in surface epithelial cells (Fig. 1) . Strong cytoplasmic staining for COX-2 was seen in parietal cells in all cases where parietal cells were present. Spotty cytoplasmic positivity for COX-2 was also seen in lamina propria plasma cells, as well as in macrophages present in the germinal centers of lymphoid aggregates (Fig. 2) . COX-2 positivity was not seen in the lymphocytes populating these lymphoid aggregates. COX-2 expression could be detected both before and after eradication of H. pylori. The mean percentage of cells staining for COX-2 was significantly higher in H. pyloriinfected mucosa compared with mucosa after successful H. pylori eradication (33.4% Ϯ 5.4 vs 18.9% Ϯ 3.3, p ϭ 0.038) 
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McCarthy et al. AJG -Vol. 94, No. 5, 1999 ( Fig. 2) . Individual patients were examined before and after eradication of H. pylori. There was a reduction of COX-2 expression in seven of 10 patients, no change in one, and a slight increase in two patients (Fig. 3) . Acute inflammation resolved in all patients after eradication of H. pylori (Table  1) , but was not well correlated with COX-2 expression (r 2 ϭ 0.47, p ϭ 0.17). COX-2 immunostaining correlated most strongly with the chronic inflammation score ( Fig. 4 ; n ϭ 20, r 2 ϭ 0.78, p Ͻ 0.001). There was a correlation for those subjects who were H. pylori infected (n ϭ 10, r 2 ϭ 0.70, p ϭ 0.024), as well as for those who were uninfected (n ϭ 10, r 2 ϭ 0.74, p ϭ 0.014).
DISCUSSION
Helicobacter pylori infection was associated with significant acute and chronic antral inflammation that was reduced by eradication of the organism, as expected. Our studies demonstrated immunohistochemical detection of COX-2 protein in antral epithelial cells, in addition to associated mononuclear cells, in the presence of H. pylori infection. In addition, parietal cells also exhibited COX-2 protein. Expression was reduced, but not eliminated, in the epithelium after successful eradication of H. pylori. Despite the reduction in COX-2 expression after H. pylori eradication, expression of COX-2 in epithelial cells remained and strongly correlated with the extent of the chronic inflammatory cell infiltrate.
Recently, other investigators have also reported the induction of gastric mucosal COX-2 expression with H. pylori infection. In a sample of H. pylori-infected and -uninfected patients, investigators in Hong Kong (8) confirmed only patchy COX-2 expression in superficial foveolar and glandular cells and mononuclear cells in the lamina propria. In H. pylori-infected mucosa, there was a significant increase in epithelial and mononuclear cell expression of the protein. However, by incubating antral mucosal biopsies from patients with H. pylori infection with highly selective COX-1 and COX-2 inhibitors, investigators from Nottingham, U.K. noted that the increase in prostaglandin production in H. pylori-infected mucosa was due primarily to the COX-1 isoform (9). These same investigators noted COX-2 expression predominantly in parietal cells in uninflamed mucosa and induction of COX-2 expression in macrophages, myofibroblasts, and endothelial cells in proximity to gastric ulcers (10) . Parietal cell immunostaining for COX-2 was also noted in our study. The physiological implications of COX-2 in parietal cell function is not known, nor has the 
